The Medicines Company (NASDAQ: MDCO) today announced the presentation of
the results of the pivotal Phase III clinical trial of the
investigational hemostatic agent RAPLIXA™ (fibrin sealant), formerly
known as Fibrocaps, at the 100 th Clinical Congress of the
American College of Surgeons in San Francisco, CA.
for The Medicines Company Announces Presentation of Investigational Hemostatic Agent RAPLIXA™ (fibrin sealant) Phase III FINISH-3 Trial Results at the 2014 Clinical Conference of the American College of Surgeons investment picks